Baseline descriptive data
| Patient | Gender | Diagnosis | Age | Age at initiation of NPPV (y) | Duration of follow up (y) |
|---|---|---|---|---|---|
| 1 | F | Spinal muscular atrophy type II | 3.83 | 2.6 | 1 |
| 2 | F | Congenital muscular dystrophy | 11.25 | 7 | 4.2 |
| 3 | F | Congenital fibre disproportionate type myopathy | 6.21 | 1.1 | 4.9 |
| 4 | F | Myotonic dystrophy | 15.21 | 13.5 | 1.5 |
| 5 | F | Fascio-scapular humeral myopathy | 13.4 | 7.9 | 5 |
| 6 | M | Congenital muscular dystrophy | 13.2 | 10.9 | 1.2 |
| 7 | F | Myotonic dystrophy | 17.78 | 13.2 | 3 |
| 8 | M | Spinal muscular atrophy type II | 16.46 | 7 | 8.6 |
| 9 | M | Duchenne muscular dystrophy | 16.79 | 14.3 | 2.4 |
| 10 | M | Spinal muscular atrophy type II | 10.22 | 8 | 2 |
| 11 | M | Nemaline rod myopathy | 14.23 | 5 | 8.5 |
| 12 | F | Muscular dystrophy | 9.55 | 6.5 | 3 |
| 13 | F | Nemaline rod myopathy | 3.4 | 2 | 1.3 |
| 14 | F | Spinal muscular atrophy type II | 6.09 | 0.5 | 4.4 |
| 15 | M | Charcot Marie tooth myopathy | 17.21 | 10 | 7 |